StreetAlpha.app
Home › Stocks › PRQR

ProQR Therapeutics N.V. (PRQR)

Healthcare
$1.04
▼ −0.95%
LAST CLOSE · NOV 20

ProQR Therapeutics develops RNA editing medicines for liver and nervous system diseases using its Axiomer platform. It last closed at $1.04 on Nov 20, down 0.95% on the day. Over the last 12 months PRQR insiders bought $1.3M of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is PRQR in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold PRQR.

Key Stats

Last 12 months
Results
Revenue
EUR 15.9M
−15.9% vs a year ago
Net income
−EUR 42.2M
−265.2% margin
Free cash flow
−EUR 53.8M
−338.3% margin
Operating margin
−273.1%
−EUR 43.4M operating income
Balance sheet
Cash & equivalents
EUR 92.4M
At Dec 31
Debt
EUR 4.9M
At Dec 31
Shareholder equity
EUR 49.4M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: EUR 1.3MEUR 1.3MFY2021FY2022: EUR 3.6MEUR 3.6MFY2022FY2023: EUR 6.5MEUR 6.5MFY2023FY2024: EUR 18.9MEUR 18.9MFY2024FY2025: EUR 15.9MEUR 15.9MFY2025

From PRQR's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 12). Last 12 months adds up the four latest quarters. Figures are in EUR. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on file yet
Reported EPS
—
Quarter ended Dec 2025
Year ago EPS
—
Same quarter last year
Revenue
$4.7M
+8.8% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Not enough quarters on file yet.
Revenue by quarter
Mar 2024: $4.5MMar '24Jun 2024: $6.3MJun '24Sep 2024: $3.8MSep '24Dec 2024: $4.3MDec '24Mar 2025: $4.5MMar '25Jun 2025: $3.8MJun '25Sep 2025: $2.9MSep '25Dec 2025: $4.7MDec '25Latest $4.7M
StreetAlpha's call on PRQRStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on PRQR
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on PRQR

Technical Analysis

PRQR · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 24% below its 20 day and 43% below its 50 day average. It is 60% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 31), near oversold. The nearest support is the 52 week low at $1.00, and the nearest resistance the Pivot R1 at $1.07.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 9.9%/day
Key levels
$2.4852 week high+138.5%
$1.71100 day average+64.4%
$1.66200 day average+59.6%
$1.4950 day average+43.3%
$1.44Swing high (Nov 13)+38.5%
$1.2920 day average+24.0%
$1.07Pivot R1+2.9%
$1.04Pivot+0.0%
$1.04Last close
$1.0052 week low−3.8%
$1.00Pivot S1−3.8%
Indicators
RSI (14)31.04Weak, oversold below 30Neutral
MACD-0.11Below its signal lineBearish
Stochastic7.2Near the bottom of its rangeOversold
ADX (14)34.9Trending down
Williams %R-91.1Oversold below −80, overbought above −20Oversold
CCI (20)-190.9Oversold below −100, overbought above 100Oversold
Rate of change−23.0%Change over 10 sessionsBearish
ATR (14)$0.10Typical daily range, 9.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PRQR

What happened before

See how PRQR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow PRQR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How PRQR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for PRQRHow many large options trades hit PRQR, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

PRQR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲28 buying vs 24 selling
  • ▼Held by funds -0.6 pts
  • ▲Funds holding +3
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding7471+4.2%
In funds' top 1021+100.0%
Held by funds57.1%57.6%−0.6 pts
New / increased11 / 1712 / 25−24.3%
Reduced / sold out16 / 811 / 11+9.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PRQR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

PRQR Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$1.3M5 buys · 2 insiders
Sold$00 sales · 0 insiders
Cluster buy: 2 insiders bought $988K between Jun 26 and Jul 17.
2026-06 bought $231K2026-07 bought $1.1MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jul 31Boer Daniel Anton deCEOBuy200,000$1.77$354K
Jul 17Bart FiliusDirectorBuy150,000$1.72$258K
Jul 9Boer Daniel Anton deCEOBuy150,000$1.74$261K
Jul 7Boer Daniel Anton deCEOBuy150,000$1.59$239K
Jun 26Bart FiliusDirectorBuy150,000$1.54$231K
Every insider buy and sale for PRQR over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See PRQR insider trades →

From SEC Form 4 filings by PRQR's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PRQR is in one of them and how their past PRQR trades turned out.

PRQR in the AI portfolios
Loading…

PRQR News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PRQR in an article yet. Here's the latest on the wider market.

PRQR in the news

About ProQR Therapeutics N.V.

ProQR is a biotechnology company based in Leiden, Netherlands, that develops RNA editing medicines. It uses its proprietary Axiomer platform, which directs enzymes already present in cells to make precise changes in RNA, to build treatments for diseases of the liver and central nervous system. Its lead candidate is in a Phase 1 trial in healthy volunteers, and its pipeline also covers Rett syndrome, MASH, a liver disease, and cardiovascular disease. The company also works with Eli Lilly on drug targets under a licensing and research collaboration.

Headquarters
Leiden